Company intelligence / Profile preview

NeuroSolv Therapeutics

Belfast, Northern Ireland, United Kingdomneurosolvtherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

NeuroSolv Therapeutics is developing Perineline™, a novel small molecule therapy for spinal cord injury. Pre-clinical data suggest it may improve neuroplasticity and neuroregeneration by temporarily removing the perineuronal net and glial scars, enabling new synapse formation. The therapy has received EMA Orphan Drug Designation and is preparing for clinical trials with leading US institutions. No published human efficacy results yet.

Therapeutic areas: Neurology
Modalities: Small molecule drug therapy (Perineline™)
Industry: Biotech

Drug pipeline

1 asset

Perineline

Preclinical

Partnerships

AscellaHealth LLC – specialty pharmacy/healthcare services partner supporting commercialization strategy and patient access initiativesUniversity of Pittsburgh – designing upcoming clinical trial for Perineline™ as of July 2024

Beyond the preview

Go deeper on NeuroSolv Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroSolv Therapeutics.